The Biggest Concern About Gray-Market Peptides Is Our Lack of Knowledge

This article highlights the challenges in obtaining reliable data on gray-market peptides, contrasting them with clinically tested drugs. It emphasizes the risks associated with these substances due to the absence of official trials and concrete information. The discussion is part of a newsletter focusing on emerging health-related products.

Originally published by theverge